EMEA-001943-PIP05-21
Key facts
| Invented name |
Ultomiris
|
| Active substance |
ravulizumab
|
| Therapeutic area |
Neurology
|
| Decision number |
P/0413/2021
|
| PIP number |
EMEA-001943-PIP05-21
|
| Pharmaceutical form(s) |
Concentrate for solution for infusion
|
| Condition(s) / indication(s) |
Treatment of amyotrophic lateral sclerosis
|
| Route(s) of administration |
Intravenous use
|
| Contact for public enquiries |
Alexion Europe SAS
E-mail: pip.enquiries.eu@alexion.com |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|